ClinicalTrials.gg
CompletedNCT02374164Updated Apr 27, 2016Results posted

Food Effect Study of Febuxostat XR in Healthy Participants

A Phase 1 interventional study of Febuxostat XR in Gout, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
20th of 29
36 · median 109
Started
2015
with 1 other
Phase 1
3 of 29
none open now
Registered
23rd of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 20th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 1, and was the 23rd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of food on the bioavailability of febuxostat after a single oral dose of 80 mg febuxostat XR and to evaluate the pharmacokinetics (PK) of febuxostat after single oral doses of 40 and 80 mg febuxostat XR.

Read the detailed description

The drug being tested in this study is called febuxostat extended- release (XR). This study is evaluating the effect of food on how febuxostat-XR moves throughout the body. This study will also look at the side effects and all safety results in people who took the study drug.

This 3-way crossover study will enroll approximately 36 participants. Eligible participants will be randomly (by chance) assigned to one of the 3 treatment sequences at 1:1:1 ratio. Sequence defines the order in which participants receive Regimens A (febuxostat XR 80 mg after a high fat meal), B (febuxostat XR 40 mg after fasting) and C (febuxostat XR 80 mg after fasting):

Sequence 1: A, B, C

Sequence 2: B, C, A

Sequence 3: C, A, B The dose in a period and the dose in the subsequent period will be separated by a minimum 7-day washout interval. This single-centre trial will be conducted in the United States.

Participants will make multiple visits to the clinic including three 4-day periods of confinement to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has an estimated ≥90 mL/min.
  2. Weighs at least 50 kg (110 pounds) and has a (BMI) from 18.0 to 30.0 kg/m\^2, inclusive, at Screening.
  3. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from the signing of the throughout the duration of the study and for 30 days after the last dose.
  4. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
  5. Able to attend all the visits scheduled in the study.
  6. Willing to refrain from strenuous exercise from Day -1 until Study Exit (Day 3 of Period 3).

Exclusion criteria

Exclusion Criteria:

  1. to Febuxostat or to any of the components of the formulation.
  2. Has received any compound within 30 days prior to the first dose of study medication.
  3. Has received febuxostat in a previous clinical study or as a therapeutic agent.
  4. Has uncontrolled, disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
  5. Has a known hypersensitivity to any xanthine oxidase (XO) inhibitor, xanthine compounds, Febuxostat or any component of the formulation of Febuxostat tablets, or to caffeine.
  6. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1 of Period 1).
  7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  8. Is pregnant or lactating or intending to become pregnant before, during, or within 30 days post last dose; or intending to donate ova during such time period.
  9. Intends to impregnate others or donate sperm during the course of this study or for 30 days post last dose.
  10. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking febuxostat XR, or a similar drug in the same class, or a disease that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.
  11. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention [eg, cholecystectomy]).
  12. Has a history of cancer, except basal cell carcinoma that has been in remission for at least 5 years prior to Day 1 of Period 1.
  13. Has a positive test result for surface antigen (HBsAg), virus (HCV) antibody or a known history of infection.
  14. Has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 28 days prior to Check-in (Day -1 of Period 1) or is unwilling to agree to abstain from nicotine-containing products. Cotinine test is positive at Screening or Check-in (Day 1 of Period 1).
  15. Has poor peripheral venous access.
  16. Has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis) or had a transfusion of any blood product within 30 days prior to Day 1 of Period 1.
  17. Has a Screening abnormal (clinically significant) (ECG).
  18. Has abnormal Screening or Day -1 of Period 1 laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: (ALT) and/or aspartate aminotransferase (AST) >1.5 x the .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABC

    Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.

    Drug: Febuxostat XR

  • Experimental
    Treatment Sequence BCA

    Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.

    Drug: Febuxostat XR

  • Experimental
    Treatment Sequence CAB

    Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.

    Drug: Febuxostat XR

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose

  2. Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post dose

  3. AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

    AUCt is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration. Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose

  4. AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States

    AUCt is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUCt) Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose

  5. AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

    AUCinf is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose

  6. AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 40 mg (Regimen B) and Febuxostate XR 80 mg (Regimen C) in Fasted States

    AUCinf is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. Participant blood samples were collected pre-dose and following a single oral dose.

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose

07

Results

Posted Apr 27, 2016

Participant flow

Healthy participants took part in the study at 1 investigative site in the United States from 2 February 2015 to 19 April 2015.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence ABCTreatment Sequence BCATreatment Sequence CAB
Started121212
Completed121212
Not completed000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence ABCTreatment Sequence BCATreatment Sequence CAB
Started121212
Completed121212
Not completed000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence ABCTreatment Sequence BCATreatment Sequence CAB
Started121112
Completed121112
Not completed000

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States
ng/mLA: Febuxostat XR 80 mg (Fed)C: Febuxostat XR 80 mg (Fasting)
Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States1020.0000 ± 398.141711531.6286 ± 906.12813
Statistical analysis
  • A: Febuxostat XR 80 mg (Fed) vs C: Febuxostat XR 80 mg (Fasting) · Point estimate: 0.720 · 90% CI 0.612 to 0.847Ratio Fed/Fasted. Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural logarithm-transformed data. Bioequivalence was reached if the value was 0.80 to 1.25.
PrimaryCmax: Maximum Observed Plasma Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post dose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States
ng/mLB: Febuxostat XR 40 mg (Fasting)C: Febuxostat XR 80 mg (Fasting)
Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States754.9167 ± 471.496301562.1389 ± 911.65824
PrimaryAUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

AUCt is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration. Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose
Reported as:
Mean · ng*hr/mL
AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States
ng*hr/mLA: Febuxostat XR 80 mg (Fed)C: Febuxostat XR 80 mg (Fasting)
AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States7605.4147 ± 2086.852627687.1220 ± 2853.12475
PrimaryAUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States

AUCt is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUCt) Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose
Reported as:
Mean · ng*hr/mL
AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States
ng*hr/mLB: Febuxostat XR 40 mg (Fasting)C: Febuxostat XR 80 mg (Fasting)
AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States3646.2021 ± 1465.072757854.2007 ± 2985.41297
PrimaryAUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States

AUCinf is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose
Reported as:
Mean · ng*hr/mL
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States
ng*hr/mLA: Febuxostat XR 80 mg (Fed)C: Febuxostat XR 80 mg (Fasting)
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States7816.0704 ± 2105.404568075.5899 ± 2826.48142
PrimaryAUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 40 mg (Regimen B) and Febuxostate XR 80 mg (Regimen C) in Fasted States

AUCinf is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. Participant blood samples were collected pre-dose and following a single oral dose.

Time frame:
Day 1 pre-dose and at multiple timepoints (up to 48 hours) post dose
Reported as:
Mean · ng*hr/mL
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 40 mg (Regimen B) and Febuxostate XR 80 mg (Regimen C) in Fasted States
ng*hr/mLB: Febuxostat XR 40 mg (Fasting)C: Febuxostat XR 80 mg (Fasting)
AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 40 mg (Regimen B) and Febuxostate XR 80 mg (Regimen C) in Fasted States3745.2837 ± 1452.717547970.7990 ± 2852.78221

Adverse events

Collected over From the first dose of study drug to 30 days after the last dose of study drug (approximately 58 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: Febuxostat XR 80 mg (Fed)—0/35 (0%)1/35 (2.9%)
B: Febuxostat XR 40 mg (Fasting)—0/36 (0%)3/36 (8.3%)
C: Febuxostat XR 80 mg (Fasting)—0/36 (0%)2/36 (5.6%)
Most frequent other events
Most frequent other events
EventA: Febuxostat XR 80 mg (Fed)B: Febuxostat XR 40 mg (Fasting)C: Febuxostat XR 80 mg (Fasting)
NauseaGastrointestinal disorders0/352/361/36
HeadacheNervous system disorders1/352/362/36

Baseline characteristics

Safety Set included all participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Mean31.3 ± 8.3735.0 ± 6.3229.1 ± 5.3531.8 ± 7.05
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Female66719
Male66517
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Hispanic or Latino56516
Not Hispanic or Latino76720
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Black or African American2237
White1010929
Region of Enrollment
Region of Enrollment(participants)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
United States12121236
Height
Height(cm)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Mean167.6 ± 8.27168.8 ± 9.98166.6 ± 12.35167.6 ± 10.08
Weight
Weight(kg)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Mean73.95 ± 10.80273.35 ± 8.86769.10 ± 8.16972.13 ± 9.335
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Treatment Sequence ABCTreatment Sequence BCATreatment Sequence CABTotal
Mean26.21 ± 1.88025.76 ± 2.32125.03 ± 2.87825.67 ± 2.376

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Mar 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2015
First posted
Feb 27, 2015
Start
Feb 2015
Primary completionActual
Mar 2015
CompletionActual
Apr 2015
Results first posted
Apr 27, 2016
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02374164
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 27, 2015
Start date
Feb 2015
Primary completion
Mar 2015
Completion
Apr 2015
Results posted
Apr 27, 2016
Last update
Apr 27, 2016

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion